The rubber hand illusion is a well-known experiment that allows manipulation of one's own body experience. The original questionnaire gauges both the illusion experience and unforeseen experiences acting as control statements. In particular, two statements pertain to the referral of touch originating from the rubber hand (RoT), and one concerns the feeling of ownership of the rubber hand (SoO). Despite its prominence, the rubber hand illusion questionnaire has not undergone thorough examination of its psychometric properties. The literature reveals a tendency to use RoT and SoO statements interchangeably. In this study, we employed Exploratory Graph Analysis to explore the item structure and compared the correlation between SoO and RoT items in various conditions. While SoO and RoT are closely linked, our findings suggest potential separation. SoO and RoT statements consistently correlate, yet hints emerge that RoT might represent a distinct facet of the illusion. Correlations diminish beyond the perihand space, indicating a nuanced relationship. Additionally, moderate relationships between control statements and those measuring the illusion suggest that even control statements are modulated by the illusion experience. This study underscores the need for further exploration into the psychometric properties of body illusion questionnaires, prompting reflections on the interpretation in light of these results.
Alzheimer's disease (AD) is a neurodegenerative disease with high prevalence in the rapidly growing elderly population in the developing world. The currently FDA approved drugs for the management of symptomatology of AD are marketed mainly as conventional oral medications. Due to their gastrointestinal side effects and lack of brain targeting, these drugs and dosage regiments hinder patient compliance and lead to treatment discontinuation. Nanotechnology-based drug delivery systems (NTDDS) administered by different routes can be considered as promising tools to improve patient compliance and achieve better therapeutic outcomes. Despite extensive research, literature screening revealed that clinical activities involving NTDDS application in research for AD are lagging compared to NTDDS for other diseases such as cancers. The industrial perspectives, processability, and cost/benefit ratio of using NTDDS for AD treatment are usually overlooked. Moreover, active and passive immunization against AD are by far the mostly studied alternative AD therapies because conventional oral drug therapy is not yielding satisfactorily results. NTDDS of approved drugs appear promising to transform this research from 'paper to clinic' and raise hope for AD sufferers and their caretakers. This review summarizes the recent studies conducted on NTDDS for AD treatment, with a primary focus on the industrial perspectives and processability. Additionally, it highlights the ongoing clinical trials for AD management.